Related Symptoms in People With Multiple Sclerosis : Results From a Retrospective Multicenter Study Francesco Patti, Clara Grazia Chisari, Claudio Solaro, Maria Donata Benedetti , Eliana Berra , Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla , Raffaella Cerqua, Gianfranco Costantino, Claudio Gasperini, Angelica Guareschi, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Margherita Russo, Francesco Saccà, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni, Mario Zappia, SA.FE. group Doi : 10.1007/s10072-020-04413-6 Abstract Introduction : The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed [...]
Lire la suiteBeneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease Isabel Espadas, Ettel Keifman, Cristina Palomo-Garo Sonia Burgaz, Concepción García, Javier Fernández-Ruiz, Rosario Moratalla Neurobiology of Disease, 2020, 141, 104892 doi : 10.1016/j.nbd.2020.104892 A B S T R A C T The antioxidant and CB2 receptor agonist properties of Δ9-tetrahydrocannabivarin (Δ9-THCV) afforded neuroprotection in experimental Parkinson's disease (PD), whereas its CB1 receptor antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. In the present study, we investigated the anti dyskinetic potential of Δ9-THCV (administered i.p. at 2 mg/kg for two weeks), which had not been investigated before. This objective was investigated [...]
Lire la suiteCette année, nous avions prévu que le 9e colloque international se déroulerait en juin, chez nous, à Strasbourg et qu’il aborderait la thématique de la recherche sur les cannabinoïdes et les cancers. Aux vues des circonstances de ce début d’année 2020, nous avons pris la décision de reporter cet évènement à une date encore inconnue. Nous allons faire au mieux pour maintenir notre programme. Vous trouverez de plus amples détails dans le communiqué ci-dessous.
Lire la suiteSARS-CoV2 induced respiratory distress : Can cannabinoids be added to anti-viral therapies to reduce lung inflammation ? Siddappa N. Byrareddy, Mahesh Mohan Brain, Behavior, and Immunity, 2020, 1-2. doi : 10.1016/j.bbi.2020.04.079 Keywords : SARS-CoV2, Rhesus macaque, Cannabinoids, Inflammation, Cytokine, Lung Coronavirus disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome coronoavirus-2 (SARS-CoV2) has emerged as a global pandemic, which was first reported in Wuhan, China. Recent reports have suggested that acute infection is associated with a cytokine superstorm, which contributes to the symptoms of fever, cough, muscle pain and in severe cases bilateral interstitial pneumonia characterized by ground glass opacity and focal chest infiltrates that can [...]
Lire la suitePrescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva Barbara Broers, Zacharie Patà, Aline Mina, James Wampfler, Christian de Saussure, Sophie Pautex Medical Cannabis & Cannabinoids, 2019, 2, 56–59 Doi : 10.1159/000498924 Abstract Background : Dementia is increasing worldwide. No effective medication is currently available for the treatment of the underlying disease and accompanying behavioral symptoms. Cannabinoids might have a beneficial effect, but clinical studies with (low-dose) synthetic THC have not been conclusive. Objective : To test the acceptability, practical aspects, and clinical outcomes of the introduction of a THC/ CBD-based oral medication in severely demented patients in a specialized [...]
Lire la suiteGPR55-Mediated Effects in Colon Cancer Cell Lines Carina Hasenoehrl, David Feuersinger, Melanie Kienzl, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 22–28 Doi : 10.1159/000496356 Abstract The cannabinoid-responsive G protein-coupled receptor GPR55 and its endogenous ligand L-α lyso-phosphatidylinositol (LPI) have been reported to play a role in several cancers. A proliferation-enhancing effect of GPR55 has been described for several cancer cell lines and LPI has been found elevated in cancer patients. The aim of this study was to investigate whether GPR55 signaling had an effect on the proliferation of colon cancer cell lines. Using cell viability assays and Western blotting, we show that stable overexpression [...]
Lire la suite4th International Medical Cannabis Conference (CannX 2019) Tel Aviv, Israel, September 9–10, 2019 Abstracts Scientific Committee Dr. Adi Aran Director of the Neuro-Pediatric Unit, Shaare Zedek Medical Center, Israel Prof. Gil Bar-Sela Head, Cancer Center, Emek Medical Center Afula, Israel Dr. Nirit Bernstein Principle Research Scientist, Plant Physiology and Nutrition Institute of Soil Water and Environmental Sciences, Volcani Center, Israel Prof. Lumir Hanus Chief Scientist, Lumir Lab, Associate Professor, Palacký University, Jerusalem Biotechnology Park, Hebrew University, Ein Kerem Campus, Senior Fellow, IEHP, Thomas Jefferson University, Philadelphia, USA, Professor Chaver and Research Fellow, Hebrew University (Ret.) Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University, Israel Dr. Shaul Lev-Ran, MHA Deputy Director, Lev Hasharon Medical Center [...]
Lire la suiteThe Intricate Influence of the Placebo Effect on Medical Cannabis and Cannabinoids Jürg Gertsch Medical Cannabis Cannabinoids, 2018, 1, 60–64 Doi : 10.1159/000489291 Abstract The botanical drug cannabis flos (inflorescence of Cannabis sativa L.) has a unique popular status as being a potent recreational drug and bona fide universal remedy (panacea). Generally, cannabinoids exert therapeutic effects in a broad range of pathophysiologies related to inflammation, pain, metabolic and stress-related conditions in preclinical animal models. However, the translation of such data to humans still lacks an evidence-based foundation. Motivated by the booming cannabis manufacturing industry and the increasing worldwide self-therapy by patients, there are cumulative accounts [...]
Lire la suiteCannabinoids and the Coronavirus Kevin P. Hill Cannabis and Cannabinoid Research, 2020, Volume 5, Number 2, Doi : 10.1089/can.2020.0035 Introduction These are uncertain times as we attempt to manage our lives during the Coronavirus Covid-19 pandemic. It is not surprising, as possible treatments for Covid-19 are discussed, that people wonder about a role for cannabinoids, another topic associated with a lack of clarity about their therapeutic efficacy. Patients commonly ask clinicians about the benefits and risks of cannabinoids and now patients have begun to ask about cannabinoids as they relate to Covid-19. This interest creates an opportunity to strengthen the therapeutic alliance between patients and [...]
Lire la suitePotential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus Mark Feldman, Reem Smoum, Raphael Mechoulam, Doron Steinberg PLoS One, April 15, 2020, 1-13. Doi : 10.1371/journal.pone.0231583 Abstract Infections caused by antibiotic-resistant strains of Staphylococcus aureus have reached epidemic proportions globally. Our previous study showed antimicrobial effects of anandamide (AEA) and arachidonoyl serine (AraS) against methicillin (MET)-resistant S. aureus (MRSA) strains, proposing the therapeutic potential of these endocannabinoid/endocannabinoid-like (EC/EC-like) agents for the treatment of MRSA. Here, we investigated the potential synergism of combinations of AEA and AraS with different types of antibiotics against MRSA grown under planktonic growth or biofilm formation. The most effective [...]
Lire la suite